JP2001507216A - 免疫療法および改良ワクチン - Google Patents
免疫療法および改良ワクチンInfo
- Publication number
- JP2001507216A JP2001507216A JP51971498A JP51971498A JP2001507216A JP 2001507216 A JP2001507216 A JP 2001507216A JP 51971498 A JP51971498 A JP 51971498A JP 51971498 A JP51971498 A JP 51971498A JP 2001507216 A JP2001507216 A JP 2001507216A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- plasmid
- tnf
- cells
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 73
- 230000001976 improved effect Effects 0.000 title abstract description 19
- 238000009169 immunotherapy Methods 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 384
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 304
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 232
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 213
- 239000000427 antigen Substances 0.000 claims abstract description 150
- 108091007433 antigens Proteins 0.000 claims abstract description 148
- 102000036639 antigens Human genes 0.000 claims abstract description 148
- 239000002773 nucleotide Substances 0.000 claims abstract description 132
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 132
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 91
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 76
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 76
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 76
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 72
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 72
- 102000003810 Interleukin-18 Human genes 0.000 claims abstract description 70
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 70
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 70
- 108090000171 Interleukin-18 Proteins 0.000 claims abstract description 69
- 108010002616 Interleukin-5 Proteins 0.000 claims abstract description 67
- 102000000743 Interleukin-5 Human genes 0.000 claims abstract description 67
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 65
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 62
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 60
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims abstract description 60
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims abstract description 60
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 58
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 58
- 102000004388 Interleukin-4 Human genes 0.000 claims abstract description 58
- 230000001105 regulatory effect Effects 0.000 claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229940124551 recombinant vaccine Drugs 0.000 claims abstract description 14
- 108010002352 Interleukin-1 Proteins 0.000 claims abstract 15
- 102000000589 Interleukin-1 Human genes 0.000 claims abstract 15
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims abstract 11
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract 11
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract 11
- 239000013612 plasmid Substances 0.000 claims description 262
- 239000000203 mixture Substances 0.000 claims description 69
- 206010028980 Neoplasm Diseases 0.000 claims description 66
- 230000002163 immunogen Effects 0.000 claims description 66
- 230000001717 pathogenic effect Effects 0.000 claims description 65
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 58
- 244000052769 pathogen Species 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 57
- 201000011510 cancer Diseases 0.000 claims description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- 208000023275 Autoimmune disease Diseases 0.000 claims description 36
- 239000013604 expression vector Substances 0.000 claims description 30
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 22
- 150000001413 amino acids Chemical group 0.000 claims description 20
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 18
- 208000007089 vaccinia Diseases 0.000 claims description 18
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 14
- 238000003259 recombinant expression Methods 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 230000003053 immunization Effects 0.000 abstract description 101
- 238000000034 method Methods 0.000 abstract description 101
- 108010041986 DNA Vaccines Proteins 0.000 abstract description 29
- 229940124590 live attenuated vaccine Drugs 0.000 abstract description 8
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract description 8
- 235000018102 proteins Nutrition 0.000 description 196
- 210000004027 cell Anatomy 0.000 description 193
- 229940117681 interleukin-12 Drugs 0.000 description 135
- 230000028993 immune response Effects 0.000 description 123
- 241000282414 Homo sapiens Species 0.000 description 115
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 102
- 108020004414 DNA Proteins 0.000 description 101
- 238000002649 immunization Methods 0.000 description 94
- 230000014509 gene expression Effects 0.000 description 92
- 239000007924 injection Substances 0.000 description 84
- 238000002347 injection Methods 0.000 description 84
- 229940090044 injection Drugs 0.000 description 83
- 210000000952 spleen Anatomy 0.000 description 83
- 108090000695 Cytokines Proteins 0.000 description 82
- 241000699670 Mus sp. Species 0.000 description 81
- 230000004044 response Effects 0.000 description 79
- 108091026890 Coding region Proteins 0.000 description 70
- 102000004127 Cytokines Human genes 0.000 description 69
- 239000013598 vector Substances 0.000 description 53
- 230000002068 genetic effect Effects 0.000 description 48
- 210000003527 eukaryotic cell Anatomy 0.000 description 45
- 238000011282 treatment Methods 0.000 description 45
- 210000001744 T-lymphocyte Anatomy 0.000 description 44
- 201000010099 disease Diseases 0.000 description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 44
- 230000000694 effects Effects 0.000 description 43
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 41
- 208000030507 AIDS Diseases 0.000 description 40
- -1 IL-10 Proteins 0.000 description 37
- 210000004698 lymphocyte Anatomy 0.000 description 32
- 210000002443 helper t lymphocyte Anatomy 0.000 description 29
- 241000701022 Cytomegalovirus Species 0.000 description 28
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 28
- 229940021995 DNA vaccine Drugs 0.000 description 27
- 241000700605 Viruses Species 0.000 description 25
- 230000003463 hyperproliferative effect Effects 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 239000012636 effector Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 22
- 238000011260 co-administration Methods 0.000 description 21
- 230000009089 cytolysis Effects 0.000 description 21
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 230000001404 mediated effect Effects 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 230000000770 proinflammatory effect Effects 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 208000031886 HIV Infections Diseases 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 238000001994 activation Methods 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 208000037357 HIV infectious disease Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 108091008874 T cell receptors Proteins 0.000 description 15
- 108700005077 Viral Genes Proteins 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 15
- 230000036039 immunity Effects 0.000 description 15
- 239000003623 enhancer Substances 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000009696 proliferative response Effects 0.000 description 14
- 229960003150 bupivacaine Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 210000004989 spleen cell Anatomy 0.000 description 13
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 12
- 241000701806 Human papillomavirus Species 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 230000008348 humoral response Effects 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000005875 antibody response Effects 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 230000008488 polyadenylation Effects 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000009258 tissue cross reactivity Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 230000024932 T cell mediated immunity Effects 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 7
- 101710132601 Capsid protein Proteins 0.000 description 7
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 102000046157 human CSF2 Human genes 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 5
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 5
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 206010037742 Rabies Diseases 0.000 description 5
- 206010042971 T-cell lymphoma Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229910052804 chromium Inorganic materials 0.000 description 5
- 239000011651 chromium Substances 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 208000026278 immune system disease Diseases 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000037983 regulatory factors Human genes 0.000 description 5
- 108091008025 regulatory factors Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 229940031567 attenuated vaccine Drugs 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102000045222 parkin Human genes 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229940033347 HIV-1 DNA vaccine Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000003172 anti-dna Effects 0.000 description 3
- 230000008349 antigen-specific humoral response Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 101100519159 Arabidopsis thaliana PCR3 gene Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100028372 COP9 signalosome complex subunit 6 Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101000860047 Homo sapiens COP9 signalosome complex subunit 6 Proteins 0.000 description 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000003931 anilides Chemical class 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001747 cinchocaine Drugs 0.000 description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960002409 mepivacaine Drugs 0.000 description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108700004030 rev Genes Proteins 0.000 description 2
- 101150098213 rev gene Proteins 0.000 description 2
- 230000007727 signaling mechanism Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108700004027 tat Genes Proteins 0.000 description 2
- 101150098170 tat gene Proteins 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 229940126580 vector vaccine Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108700026215 vpr Genes Proteins 0.000 description 2
- 101150024249 vpr gene Proteins 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MQIXMJWNEKUAOZ-KCFXOXMASA-N Cinnamoylcocaine Natural products O=C(O[C@H]1[C@H](C(=O)OC)[C@@H]2N(C)[C@H](C1)CC2)/C=C/c1ccccc1 MQIXMJWNEKUAOZ-KCFXOXMASA-N 0.000 description 1
- NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000711450 Infectious bronchitis virus Species 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 1
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 1
- 102100039898 Interleukin-18 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940013767 bupivacaine injection Drugs 0.000 description 1
- 229960003369 butacaine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000052620 human IL10 Human genes 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 102000043959 human IL18 Human genes 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000055228 human IL5 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- YGSFZBYOMFZJPV-UHFFFAOYSA-N isobucaine Chemical compound CC(C)CNC(C)(C)COC(=O)C1=CC=CC=C1 YGSFZBYOMFZJPV-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- LJQWYEFHNLTPBZ-UHFFFAOYSA-N metabutoxycaine Chemical compound CCCCOC1=C(N)C=CC=C1C(=O)OCCN(CC)CC LJQWYEFHNLTPBZ-UHFFFAOYSA-N 0.000 description 1
- 229950004316 metabutoxycaine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- MQIXMJWNEKUAOZ-UYCDZTDFSA-N methyl (1s,3s,4r,5r)-8-methyl-3-[(e)-3-phenylprop-2-enoyl]oxy-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)\C=C\C1=CC=CC=C1 MQIXMJWNEKUAOZ-UYCDZTDFSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- OWWVHQUOYSPNNE-UHFFFAOYSA-N parethoxycaine Chemical compound CCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 OWWVHQUOYSPNNE-UHFFFAOYSA-N 0.000 description 1
- 229960003899 parethoxycaine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- XIMBESZRBTVIOD-UHFFFAOYSA-N piperidine-2-carboxamide Chemical compound NC(=O)C1CCCCN1 XIMBESZRBTVIOD-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 244000000066 protist pathogen Species 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.a)IL-12、GM-CSF、IL-1,TNF-α、TNF-β、IL-2、IL-4、IL-5、IL-10、IL -15、IL-18、およびBL-1を含むグループから選択される免疫調節タンパク質をコ ードするヌクレオチド配列、およびb)免疫原をコードするヌクレオチド配列から なる、プラスミド。 2.上記の免疫原が、制御要素に制御可能なように連結された標的タンパク質 (この標的タンパク質は病原体抗原、癌関連抗原、または自己免疫疾患関連細胞 に結合された抗原をコードする)である、請求項1のプラスミド。 3.上記の免疫原がHIV抗原である、請求項1のプラスミド。 4.上記の免疫調節タンパク質が一本鎖IL-12である、請求項1のプラスミド。 5.IL-12、GM-CSF、IL-1、TNF-α、TNF-β、IL-2、IL-4、IL-5、IL-10、IL-1 5、IL-18、およびBL-1を含むグループから選択される免疫調節タンパク質の複数 をコードするヌクレオチド配列からなり、上記ヌクレオチド配列の各々が制御要 素に制御可能なように連結された、請求項1のプラスミド。 6.上記の免疫調節タンパク質の複数をコードするヌクレオチド配列からなる 、請求項1のプラスミド。 7.請求項1のプラスミドからなる薬学組成物。 8.請求項1のプラスミドを個体に投与することからなる、病原体に対して個 体を免疫化する方法。 9.IL-12、GM-CSF、IL-1、TNF-α、TNF-β、IL-2、IL-4、IL-5、IL-10、IL-1 5、IL-18、およびBL-1を含むグループから選択される免疫調節タンパク質をコー ドする、制御要素に制御可能なように連結された1番目のヌクレオチド配列から なるプラスミドと、免疫原をコードするヌクレオチド配列からなる2番目のプラ スミドを含む、2つ以上のプラスミドからなる組成物。 10.2番目のプラスミドが病原体抗原、癌関連抗原、または自己免疫疾患関連 細胞に結合された抗原からなるグループから選択される免疫原をコードする、請 求項9の組成物。 11.上記免疫原がHIV-1抗原である場合の、請求項9の組成物。 12.上記の免疫調節タンパク質が一本鎖IL-12である場合の、請求項9の組成物 。 13.上記の1番目のプラスミドがIL-12、GM-CSF、IL-1、TNF-α、TNF-β、IL-2 、IL-4、IL-5、IL-10、IL-15、IL-18、およびBL-1を含むグループから選択され る免疫調節タンパク質の複数をコードするヌクレオチド配列からなる場合の、免 疫調節タンパク質をコードするヌクレオチド配列の各々が制御要素に制御可能な ように連結された、請求項9の組成物。 14.制御要素に制御可能なように連結されたIL-12、GM-CSF、IL-1、TNF-α、T NF-β、IL-2、IL-4、IL-5、IL-10、IL-15、IL-18、およびBL-1を含むグループか ら選択される免疫調節タンパク質をコードするヌクレオチド配列からなる3番目 のプラスミドからなる、請求項9の組成物。 15.上記の1番目のプラスミドが、上記の免疫調節タンパク質をコードするヌ クレオチド配列の複数からなる、請求項9の組成物。 16.請求項9の組成物からなる薬学組成物。 17.請求項9の組成物を個体に投与することからなる、個体を病原体に対して 免疫化する方法。 18.制御要素に制御可能なように連結されたIL-12、GM-CSF、IL-1、TNF-α、T NF-β、IL-2、IL-4、IL-5、IL-10、IL-15、IL-18、およびBL-1を含むグループか ら選択される免疫調節タンパク質をコードするヌクレオチド配列、および免疫原 をコードするヌクレオチド配列からなる組換えワクチン。 19.病原体抗原、癌関連抗原、または自己免疫疾患関連細胞に結合された抗原 からなるグループから上記の免疫原が選択される、請求項18の組換えワクチン。 20.上記ワクチンが組換えワクシニアワクチンである、請求項18の組換えワク チン。 21.上記の免疫調節タンパク質が一本鎖IL-12である、請求項18の組換えワク チン。 22.上記の免疫原が病原体抗原である、請求項18の組換えワクチン。 23.IL-12、GM-CSF、IL-1、TNF-α、TNF-β、IL-2、IL-4、IL-5、IL-10、IL-1 5、IL-18、およびBL-1を含むグループから選択される免疫調節タンパク質の複数 をコードする(各々が制御要素に制御可能なように連結された)ヌクレオチド配列 からなる、請求項18の組換えワクチン。 24.上記の免疫調節タンパク質をコードするヌクレオチド配列の複数からなる 、請求項18の組換えワクチン。 25.請求項18の組換えワクチンを個体に投与することからなる、個体を病原体 に対して免疫化する方法。 26.制御要素に制御可能なように連結されたIL-12、GM-CSF、IL-1、TNF-α、T NF-β、IL-2、IL-4、IL-5、IL-10、IL-15、IL-18、およびBL-1を含むグループか ら選択される免疫調節タンパク質をコードするヌクレオチド配列からなる、弱毒 生病原体。 27.IL-12、GM-CSF、IL-1、TNF-α、TNF-β、IL-2、IL-4、IL-5、IL-10、IL-1 5、IL-18、およびBL-1を含むグループから選択される免疫調節タンパク質の複数 をコードする(各々が制御要素に制御可能なように連結された)ヌクレオチド配列 からなる、請求項26の弱毒生病原体。 28.上記の免疫調節タンパク質をコードするヌクレオチド配列の複数からなる 、請求項26の弱毒生病原体。 29.請求項26の弱毒生病原体を個体に投与することからなる、個体を病原体に 対して免疫化する方法。 30.一本鎖IL-12をコードするヌクレオチド配列からなるプラスミド。 31.図14に示すアミノ酸配列またはその免疫調節断片を有する、実質的に純粋 なBL-1タンパク質。 32.請求項21のタンパク質をコードする核酸配列からなる、組換え発現ベクタ ー。 33.図14のヌクレオチド配列からなる、請求項22の組換え発現ベクター。 34.請求項21のタンパク質上のエピトープに結合する、単離された抗体。 35.抗体がモノクローン抗体である、請求項24の抗体。 36.請求項22の核酸分子、および薬学上受容可能な担体からなる、薬学組成物 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2861396P | 1996-10-23 | 1996-10-23 | |
US60/028,613 | 1996-10-23 | ||
PCT/US1997/019502 WO1998017799A1 (en) | 1996-10-23 | 1997-10-23 | Immunotherapy and improved vaccines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008045969A Division JP2008194046A (ja) | 1996-10-23 | 2008-02-27 | 免疫療法および改良ワクチン |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001507216A true JP2001507216A (ja) | 2001-06-05 |
Family
ID=21844431
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51971498A Ceased JP2001507216A (ja) | 1996-10-23 | 1997-10-23 | 免疫療法および改良ワクチン |
JP2008045969A Pending JP2008194046A (ja) | 1996-10-23 | 2008-02-27 | 免疫療法および改良ワクチン |
JP2009164572A Pending JP2009232860A (ja) | 1996-10-23 | 2009-07-13 | 免疫療法および改良ワクチン |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008045969A Pending JP2008194046A (ja) | 1996-10-23 | 2008-02-27 | 免疫療法および改良ワクチン |
JP2009164572A Pending JP2009232860A (ja) | 1996-10-23 | 2009-07-13 | 免疫療法および改良ワクチン |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0958364A4 (ja) |
JP (3) | JP2001507216A (ja) |
KR (4) | KR100780158B1 (ja) |
CN (2) | CN1257976C (ja) |
AU (1) | AU729579B2 (ja) |
BR (1) | BR9712852A (ja) |
CA (3) | CA2745736C (ja) |
WO (1) | WO1998017799A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002538090A (ja) * | 1999-03-03 | 2002-11-12 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ワクチンおよび遺伝子治療組成物およびその作製および使用法 |
JP2008536476A (ja) * | 2005-04-20 | 2008-09-11 | ディナベック株式会社 | アルツハイマー病の治療のための安全性に優れた鼻腔内投与可能遺伝子ワクチン |
JP2016517402A (ja) * | 2013-03-15 | 2016-06-16 | バイオベン・3・リミテッドBioven 3 Limited | 自己組織化合成タンパク質(Self−AssemblingSyntheticProteins) |
US10646563B2 (en) | 2008-04-04 | 2020-05-12 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528312B1 (en) | 1998-05-06 | 2003-03-04 | Transgene S.A. | Use of G-actin for improving transfection of a polynucleotide into a cell |
AU2002301344B2 (en) * | 1998-05-06 | 2005-01-13 | Association Francais Contre Les Myopathies | Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy |
AU3827699A (en) * | 1998-05-07 | 1999-11-23 | Akzo Nobel N.V. | Use of interleukin-18 as vaccine adjuvant |
US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
KR20020084841A (ko) | 1999-04-23 | 2002-11-11 | 파멕사 에이/에스 | Il5 활성을 다운-조절하는 방법 |
GEP20053446B (en) * | 1999-05-13 | 2005-02-25 | Wyeth Corp | Adjuvant Combination Formulations |
US6943152B1 (en) * | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
EP1246848A1 (en) * | 1999-12-27 | 2002-10-09 | University Of Manitoba | GENETIC VACCINES FOR THE PRODUCTION OF CHICKEN EGG-YOLK ANTIBODIES AGAINST ENTEROTOXIGENIC i ESCHERICHIA COLI /i AND OTHER PATHOGENS |
US7754201B2 (en) | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
US6544780B1 (en) | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
US7092633B2 (en) | 2000-11-14 | 2006-08-15 | University Of Texas System Board Of Regents | System and method for configuring optical circuits |
JP2002221520A (ja) * | 2001-01-29 | 2002-08-09 | Sumitomo Chem Co Ltd | 免疫型の予測方法 |
CN1840656B (zh) * | 2001-03-27 | 2010-06-02 | 萨斯喀彻温大学 | 培养环状病毒的方法 |
KR20030012199A (ko) * | 2001-07-31 | 2003-02-12 | (주)지노첵 | 사이토카인 유전자를 유효성분으로 포함하는 dna 백신 |
AU2003214044B8 (en) * | 2002-01-17 | 2008-11-13 | Polymun Scientific Immunbiologische Forschung Gmbh | Anti-idiotypic antibody inducing HIV-1 neutralizing antibodies |
GB0223696D0 (en) * | 2002-10-14 | 2002-11-20 | Ml Lab Plc | Improved immunotherapy |
CN1756845A (zh) | 2002-11-12 | 2006-04-05 | A·B·德塞罗斯 | 腺病毒载体疫苗 |
JP2006514549A (ja) | 2002-12-16 | 2006-05-11 | アメリカ合衆国 | Il−15を発現する組換えワクチンウイルスおよびその使用方法 |
US20040146486A1 (en) * | 2003-01-24 | 2004-07-29 | Juan Sun | Hybrid vector system for use as a vaccine |
WO2004069272A2 (en) * | 2003-02-05 | 2004-08-19 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
WO2005051991A2 (en) | 2003-11-24 | 2005-06-09 | Sidney Kimmel Cancer Center | Mucin antigen vaccine |
US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
KR101157694B1 (ko) | 2003-12-17 | 2012-06-20 | 와이어쓰 엘엘씨 | 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법 |
EA009559B1 (ru) | 2003-12-17 | 2008-02-28 | Элан Фармасьютикелз, Инк. | КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
WO2008008360A1 (en) | 2006-07-13 | 2008-01-17 | Wyeth | Production of glycoproteins |
ES2541546T3 (es) | 2006-11-03 | 2015-07-21 | Wyeth Llc | Sustancias que inhiben la glucólisis en cultivo celular |
EP2115126B1 (en) | 2007-03-02 | 2015-04-08 | Wyeth LLC | Use of copper and glutamate in cell culture for production of polypeptides |
WO2010051820A1 (en) * | 2008-11-10 | 2010-05-14 | Aarhus Universitet | Multiplexed cytokine vaccination |
WO2010126766A1 (en) | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
US20130197612A1 (en) * | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
CN102370979B (zh) * | 2011-10-10 | 2013-05-01 | 中国人民解放军第四军医大学 | 一种针对人TNF-α分子的自体疫苗的构建方法 |
US20150190499A1 (en) | 2012-07-19 | 2015-07-09 | Zoetis Llc | Bovine influenza c virus compositions |
AU2013295770A1 (en) | 2012-07-27 | 2015-01-29 | Zoetis Services Llc | Tick toxin compositions |
EA034110B1 (ru) * | 2013-03-15 | 2019-12-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Противораковые вакцины и способы лечения с их применением |
JP2016512841A (ja) | 2013-03-15 | 2016-05-09 | ゾエティス・サービシーズ・エルエルシー | 多価ワクチンによるb.トレハロシ感染に対するウシの干渉効果 |
SI3334454T1 (sl) | 2015-08-14 | 2023-02-28 | Zoetis Services Llc | Sestave mycoplasma bovis |
CA3010977A1 (en) | 2016-01-11 | 2017-07-20 | Zoetis Services Llc | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
KR20190141695A (ko) | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
AU2019359890A1 (en) | 2018-10-17 | 2021-06-03 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
WO2020132595A1 (en) * | 2018-12-21 | 2020-06-25 | The Regents Of The University Of California | Il-10-containing vaccines and uses thereof |
CN110170049B (zh) * | 2019-06-01 | 2023-07-04 | 山西农业大学 | 一种用于鸡球虫病活疫苗的细胞因子基因佐剂 |
WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU584305B2 (en) * | 1982-10-11 | 1989-05-25 | British Technology Group Limited | Polypeptides useful in vaccination against enteroviruses |
DE3751664T2 (de) * | 1986-08-01 | 1996-06-05 | Commw Scient Ind Res Org | Rekombinanter impfstoff |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5238823A (en) * | 1990-08-22 | 1993-08-24 | Veterinary Infectious Disease Organization | Interleukin-2-leukotoxin gene fusions and uses thereof |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
CA2201592A1 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
-
1997
- 1997-10-23 CN CNB97180897XA patent/CN1257976C/zh not_active Expired - Lifetime
- 1997-10-23 CA CA2745736A patent/CA2745736C/en not_active Expired - Lifetime
- 1997-10-23 CN CNA2006100718690A patent/CN1868545A/zh active Pending
- 1997-10-23 EP EP97912961A patent/EP0958364A4/en not_active Withdrawn
- 1997-10-23 KR KR1019997003507A patent/KR100780158B1/ko not_active IP Right Cessation
- 1997-10-23 JP JP51971498A patent/JP2001507216A/ja not_active Ceased
- 1997-10-23 KR KR1020057008602A patent/KR20050053796A/ko not_active Application Discontinuation
- 1997-10-23 CA CA2751712A patent/CA2751712C/en not_active Expired - Lifetime
- 1997-10-23 KR KR1020077024846A patent/KR20070108418A/ko not_active Application Discontinuation
- 1997-10-23 AU AU50022/97A patent/AU729579B2/en not_active Expired
- 1997-10-23 KR KR1020047021499A patent/KR100629835B1/ko not_active IP Right Cessation
- 1997-10-23 WO PCT/US1997/019502 patent/WO1998017799A1/en not_active Application Discontinuation
- 1997-10-23 CA CA002269074A patent/CA2269074A1/en not_active Abandoned
- 1997-10-23 BR BR9712852-0A patent/BR9712852A/pt not_active Application Discontinuation
-
2008
- 2008-02-27 JP JP2008045969A patent/JP2008194046A/ja active Pending
-
2009
- 2009-07-13 JP JP2009164572A patent/JP2009232860A/ja active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002538090A (ja) * | 1999-03-03 | 2002-11-12 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ワクチンおよび遺伝子治療組成物およびその作製および使用法 |
JP2008536476A (ja) * | 2005-04-20 | 2008-09-11 | ディナベック株式会社 | アルツハイマー病の治療のための安全性に優れた鼻腔内投与可能遺伝子ワクチン |
US10646563B2 (en) | 2008-04-04 | 2020-05-12 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using |
US11027009B2 (en) | 2008-04-04 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same |
JP2016517402A (ja) * | 2013-03-15 | 2016-06-16 | バイオベン・3・リミテッドBioven 3 Limited | 自己組織化合成タンパク質(Self−AssemblingSyntheticProteins) |
US10736948B2 (en) | 2013-03-15 | 2020-08-11 | In3Bio Ltd. | Epidermal growth factor fusion proteins with mutant cholera toxin B subunits |
US11419923B2 (en) | 2013-03-15 | 2022-08-23 | In3Bio Ltd. | Self-assembling synthetic proteins |
Also Published As
Publication number | Publication date |
---|---|
EP0958364A4 (en) | 2001-10-31 |
CN1242045A (zh) | 2000-01-19 |
KR100629835B1 (ko) | 2006-09-29 |
AU729579B2 (en) | 2001-02-01 |
WO1998017799A1 (en) | 1998-04-30 |
CA2269074A1 (en) | 1998-04-30 |
CA2751712A1 (en) | 1998-04-30 |
JP2009232860A (ja) | 2009-10-15 |
KR100780158B1 (ko) | 2007-11-27 |
BR9712852A (pt) | 1999-11-16 |
KR20070108418A (ko) | 2007-11-09 |
KR20050053796A (ko) | 2005-06-08 |
KR20000052710A (ko) | 2000-08-25 |
CN1868545A (zh) | 2006-11-29 |
JP2008194046A (ja) | 2008-08-28 |
KR20050008860A (ko) | 2005-01-21 |
CA2745736A1 (en) | 1998-04-30 |
AU5002297A (en) | 1998-05-15 |
CN1257976C (zh) | 2006-05-31 |
CA2751712C (en) | 2016-11-22 |
EP0958364A1 (en) | 1999-11-24 |
CA2745736C (en) | 2016-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001507216A (ja) | 免疫療法および改良ワクチン | |
Kim et al. | In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. | |
WO1998017799A9 (en) | Immunotherapy and improved vaccines | |
US8202847B2 (en) | Mutant human CD80 and compositions for and methods of making and using the same | |
KR100620481B1 (ko) | 개선된 백신 | |
CN102781952B (zh) | 编码rantes的核酸分子、包含其的组合物以及其使用方法 | |
AU774265B2 (en) | Vaccines and gene therapy compositions and methods of making and using the same | |
JP2004525604A (ja) | Hivアクセサリータンパク質をコードするdnaワクチン | |
JP2004515213A (ja) | ワクチン、免疫療法剤及びそれらの利用 | |
KR20030076217A (ko) | 코스미드 dna 작제물 및 이를 제조하고 이용하는 방법 | |
Kim | Rational vaccine design through the use of molecular adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070326 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070919 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080227 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080417 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080814 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100726 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100729 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100901 |